Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCstone Pharma-B
Stock Code02616
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為一間臨床階段生物製藥公司,專注於開發及商業化創新腫瘤免疫及分子靶向藥物,以滿足癌症治療的殷切醫療需求。
Listing Date2019-02-26
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 上海市 浦東新區 張衡路1000號 25號樓 郵編:201203
Business Address (Hong Kong)香港 灣仔 皇后大道東248號 陽光中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitecstonepharma.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 12.00 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-02-14 to 2019-02-19
Global Offering Shares186,396,000 shares
HK Public Offer Shares (Initial)18,640,000 shares (10.0%)
Public Offer Lots (Initial)37,280lots (Pool A18,640lots,Pool B18,640lots)
International Placing Shares (Initial)167,756,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO984,051,532 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share33.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,236,752,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 9.65B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status亏损约人民币344.0百万元
Period-End Cash Balance人民币83.4百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment約412百萬美元

Financial Data

Unit: '000 RMB
Income Statement
Item 20162017
Other income and gains, net 1879,185
Administrative expenses -15,050-39,335
Net finance costs -240-60
Profit for the year -253,039-342,547
Profit attributable to owners -246,091-308,904
Balance Sheet
Item 20162017
Cash and cash equivalents 59,53983,390
Total current assets 824,816545,260
Total assets 826,139564,280
Total current liabilities 59,184113,228
Total liabilities 59,184113,228
Total equity 766,955451,052
Equity attributable to owners 712,688426,338
Cash Flow Statement
Item 201620172018-09
Net cash from operating activities -213,006-240,186
Net cash from investing activities -753,469268,300
Net cash from financing activities 1,010,503-300
Net increase in cash 44,02827,814
Depreciation of PP&E 678113,742
Amortisation of intangible assets 210111
Purchase of PP&E -1,101-12,130-4,432
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 12.86
First Day OpenHK$ 13.32
First Day Change7.17%
First Day Volume57486000.0
First Day Turnover784345000.0
Use of Proceeds
1、預計約622.17百萬港元(相當于所得款項凈額的30.0%)將分配至以下我們 的核心候選產品; 2、預計約829.56百萬港元(相當于所得款項凈額的40.0%)將分配至以下管線 中其余八種臨床及IND階段候選藥物; 3、預計約414.78百萬港元(相當于所得款項凈額的20%)將用于為研發管線中 其余五種候選藥物以及研發和尋求新候選藥物的許可提供資金; 4、預計約207.39百萬港元(相當于所得款項凈額的10%)將用作營運資金及其 他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291
Overall Coordinators (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Boyu Capital Opportunities Master Fund 156,936,000 HKD — 7.02% — 6 months 2019-08-26
2 GIC Private Limited 313,872,000 HKD — 14.03% — 6 months 2019-08-26
3 Indus Capital Partners,LLC 117,702,000 HKD — 5.26% — 6 months 2019-08-26
4 Ishana Capital Limited 156,936,000 HKD — 7.02% — 6 months 2019-08-26

Directors & Management

PositionChinese nameEnglish Name
Chairman江寧軍—
Company Secretary楊靜文—
No director data available.

Major Shareholders

Major Shareholders & HoldingsWuXi Healthcare Ventures持有29.76%;Graceful Beauty Limited持有14.93%;正則原石持有9.98%。
About this page

This page shows Cstone Pharma-B (02616) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect